Business Context and Reporting Period
Company: Weyco Group, Inc. (WEYS)
Filing Type: Form 8-K (Current Report)
Date of Report: March 4, 2025
Reporting Period: Events occurring on March 3, 2025, and March 4, 2025.
Key Financial Metrics
This filing does not contain financial performance data. Revenue, profit, cash flow, margins, debt, and liquidity metrics are not reported in this document.
Material Changes
- Board Composition Change: Mr. Robert Feitler resigned from the Board of Directors effective February 28, 2025.
- Listing Non-Compliance: Due to the resignation, the Company no longer satisfies Nasdaq Listing Rule 5605(b)(1), which mandates that a majority of the Board be composed of independent directors.
- Regulatory Notification: On March 4, 2025, Nasdaq confirmed the Company's non-compliance status.
Outlook, Risks, and Management Commentary
- Cure Period: Nasdaq has granted a cure period to regain compliance. The deadline is the earlier of the next annual shareholders meeting or February 28, 2026. If the next annual meeting occurs before August 27, 2025, compliance must be evidenced by August 27, 2025.
- Management Action: The Company is actively searching for candidates to fill the Board vacancy.
- Risk of Delisting: Management explicitly states there can be no assurance that the Company will successfully regain compliance within the applicable cure period.
Investor Verification Checklist
- Verify the current composition of the Board of Directors to confirm the number of independent directors.
- Monitor the Company's progress in recruiting a new independent director to meet the majority requirement.
- Check for any subsequent 8-K filings regarding the outcome of the search or further communications from Nasdaq.
- Review the date of the next annual shareholders meeting to determine the specific compliance deadline.